Inhibition of the Tumor-initiating Ability of the Potent Carcinogen 7,12-Dimethylbenz(a)anthracene by the Weak Tumor Initiator 1,2,3,4-Dibenzanthracene

T. J. Slaga, R. K. Boutwell

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Aryl hydrocarbon hydroxylase (AHH) in mouse epidermis was inducible by topical application of several tumor-initiating polycyclic aromatic hydrocarbons. The weak tumor initiator 1,2,3,4-dibenazanthracene (1,2,3,4-DBA), at dose level of 200 nmoles, increased AHH activity more than 10-fold over that of the acetone controls at 12 hr after treatment. Administration of the same quantity of the potent initiator 7,12-dimethylbenz(a)anthracene (DMBA) increased AHH activity approximately 4-fold over that of the control at 12 hr after treatment. Simultaneous treatment with 200 or 100 nmoles of DMBA and 1,2,3,4-DBA resulted in AHH activity that was 546 and 732% that of the controls, respectively, 12 hr after treatment; this was less AHH activity than was observed when 1,2,3,4-DBA was administered alone. Doses of 20 nmoles or more of 1,2,3,4-DBA, when given at about the same time as DMBA, effectively inhibited DMBA initiation of skin tumors in a two-stage system of tumorigenesis. The results suggest that the weak initiator 1,2,3,4-DBA may program the epidermal AHH system to metabolize the strong carcinogen DMBA to noncarcinogenic intermediate^).

Original languageEnglish (US)
Pages (from-to)128-133
Number of pages6
JournalCancer Research
Volume37
Issue number1
StatePublished - Jan 1977
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Inhibition of the Tumor-initiating Ability of the Potent Carcinogen 7,12-Dimethylbenz(a)anthracene by the Weak Tumor Initiator 1,2,3,4-Dibenzanthracene'. Together they form a unique fingerprint.

Cite this